<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04377945</url>
  </required_header>
  <id_info>
    <org_study_id>BK-JM-201</org_study_id>
    <nct_id>NCT04377945</nct_id>
  </id_info>
  <brief_title>Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components</brief_title>
  <acronym>SHINE</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson's Disease Patients With Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and Its Individual Components</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bukwang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bukwang Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two-part, double-blind, placebo-controlled, randomized, multicenter Phase 2&#xD;
      clinical trial of JM-010 in patients with Parkinson's Disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two-part, Phase 2, double-blind, placebo-controlled, randomized, multicentre study.&#xD;
&#xD;
      Subjects with a diagnosis of PD and dyskinesias in PD will complete a Screening Visit to&#xD;
      assess eligibility to participate in the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 12, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Unified Dyskinesia Rating Scale (UDysRS)</measure>
    <time_frame>Week 12</time_frame>
    <description>Unified Dyskinesia Rating Scale (Scoring range: 0-104), higher score indicates more severe dyskinesia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS)</measure>
    <time_frame>Week 12</time_frame>
    <description>Movement Disorder Society Unified Parkinson's Disease Rating Scale (Part III Scoring range: 0-137), higher score indicates more severe motor impairment</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">188</enrollment>
  <condition>Dyskinesias</condition>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Part 1, JM-010 component Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1, JM-010 component Group A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, JM-010 component Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1, JM-010 component Group B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, JM-010 component Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1, JM-010 component Group C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part 1, Placebo Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, JM-010 combination Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2, JM-010 combination Group A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, JM-010 combination Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2, JM-010 combination Group B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, JM-010 component Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2, JM-010 component Group C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part 2, Placebo Group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 1, JM-010 component Group A</intervention_name>
    <description>JM-010 component Group A</description>
    <arm_group_label>Part 1, JM-010 component Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 1, JM-010 component Group B</intervention_name>
    <description>JM-010 component Group B</description>
    <arm_group_label>Part 1, JM-010 component Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 1, JM-010 component Group C</intervention_name>
    <description>JM-010 component Group C</description>
    <arm_group_label>Part 1, JM-010 component Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 1, Placebo Group</intervention_name>
    <description>Placebo Group</description>
    <arm_group_label>Part 1, Placebo Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 2, JM-010 combination Group A</intervention_name>
    <description>JM-010 combination Group A</description>
    <arm_group_label>Part 2, JM-010 combination Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 2, JM-010 combination Group B</intervention_name>
    <description>JM-010 combination Group B</description>
    <arm_group_label>Part 2, JM-010 combination Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 2, JM-010 component Group C</intervention_name>
    <description>JM-010 component Group C</description>
    <arm_group_label>Part 2, JM-010 component Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 2, Placebo Group</intervention_name>
    <description>Placebo Group</description>
    <arm_group_label>Part 2, Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is able to read, understand, and provide written, dated informed consent prior to&#xD;
             Screening Visit.&#xD;
&#xD;
          -  Is male or female, between 18 and 80 years of age at Screening Visit.&#xD;
&#xD;
          -  Is diagnosed with idiopathic PD that meets UK Parkinson's Disease Society (UKPDS)&#xD;
             Brain Bank Clinical Diagnostic Criteria&#xD;
&#xD;
          -  Has experienced dyskinesia&#xD;
&#xD;
          -  Has stable peak-effect dyskinesia&#xD;
&#xD;
          -  Has more than one hour of &quot;ON&quot; time with troublesome dyskinesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has undergone surgery for the treatment of PD&#xD;
&#xD;
          -  Has a current diagnosis of Substance Use&#xD;
&#xD;
          -  Has psychiatric diagnosis of acute psychotic disorder or other psychiatric diagnoses&#xD;
&#xD;
          -  Has current seizure disorders requiring treatment with anticonvulsants.&#xD;
&#xD;
        Other criteria related to other medical conditions to be referred to the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sooyeon Park</last_name>
    <role>Study Director</role>
    <affiliation>Bukwang Pharmaceutical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sooyeon Park</last_name>
    <phone>82-2-828-8240</phone>
    <email>bk_jm010@bukwang.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bukwang Investigator site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bukwang Investigator site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2020</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

